iSpecimen Inc. Common Stock (ISPC)
Stock · NASDAQ · Health Care
$0.95as of 10/16/2026
Price chart
Active signals
ISPC Signal Track Record
How signals performed across all stocks →What ISPC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band BreakdownActive now | 25 | -14.8% | 36% | September 23, 2026 |
| Volume Spike | 15 | -25.1% | 20% | September 24, 2026 |
| Bollinger Band Breakout | 13 | -25.0% | 23% | September 9, 2025 |
| 200-Day Moving Average TouchActive now | 3 | -24.8% | 0% | July 26, 2023 |
| Any 20-session window (baseline) | -11.7% | 26% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ISPC
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The com…
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Employees
- 7
- Website
- www.ispecimen.com/
Fundamentals
- 1-day range
- $0.97$1.05
- Market cap
- $3.35M
- P/E (trailing)
- —
- P/E (forward)
- -1.30
- EPS (trailing)
- $-52.63
- Dividend yield
- —
- Beta
- 1.79
- Avg. volume
- 664.1K
How iSpecimen Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Apr 1, 2026 · via SEC EDGAR / Finnhub
iSpecimen Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ISPCiSpecimen Inc. Common Stock$0.917▼ 10.97%Market cap $3.35MP/E —$1.02$36.32
- BIAFbioAffinity Technologies Inc. Common Stock$3.73▼ 5.81%Market cap $4.12MP/E —$4.56$80.7
- ONMDOneMedNet Corp Class A Common Stock$4.51▼ 5.05%Market cap $37.18MP/E —$4.9$42.2
- MXCTMaxCyte Inc. Common Stock$1.3▲ 0.00%Market cap $118.91MP/E —$0.643$1.87
- OABIOmniAb Inc. Common Stock$4.59▼ 2.96%Market cap $324.74MP/E —$1.3$5.43
- NRCNRC Health Common Stock$20.15▼ 4.55%Market cap $430.67MP/E 79.70$11.01$23.68
- ABSIAbsci Corporation Common Stock$8.25▼ 7.09%Market cap $1.29BP/E —$2.24$12.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ISPC iSpecimen Inc. Common Stock | $3.35M | — | $0.917 | ▼ 10.97% | $1.02$36.32 |
| BIAF bioAffinity Technologies Inc. Common Stock | $4.12M | — | $3.73 | ▼ 5.81% | $4.56$80.7 |
| ONMD OneMedNet Corp Class A Common Stock | $37.18M | — | $4.51 | ▼ 5.05% | $4.9$42.2 |
| MXCT MaxCyte Inc. Common Stock | $118.91M | — | $1.3 | ▲ 0.00% | $0.643$1.87 |
| OABI OmniAb Inc. Common Stock | $324.74M | — | $4.59 | ▼ 2.96% | $1.3$5.43 |
| NRC NRC Health Common Stock | $430.67M | 79.70 | $20.15 | ▼ 4.55% | $11.01$23.68 |
| ABSI Absci Corporation Common Stock | $1.29B | — | $8.25 | ▼ 7.09% | $2.24$12.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- iSpecimen Supports Hospital Validation of New Chemistry AnalyzerYahoo · 9/29/2026
- Stay updated with the stocks that are on the move in today's after-hours session.ChartMill · 9/24/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
iSpecimen Supports Hospital Validation of New Chemistry Analyzer
iSpecimen has announced it is supporting a hospital’s validation of a new chemistry analyzer. The collaboration shows the company’s technology is being tested in a real clinical setting, which could lead to wider adoption. The move may strengthen iSpecimen’s position in the medical device market.
iSpecimen Supports Hospital Validation of New Chemistry Analyzer. iSpecimen has announced it is supporting a hospital’s validation of a new chemistry analyzer. The collaboration shows the company’s technology is being tested in a real clinical setting, which could lead to wider adoption. The move may strengthen iSpecimen’s position in the medical device market.